AstraZeneca's first quarter profits jump 74%


Save Story
Leer en español

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca says first quarter earnings jumped 74%, buoyed by emerging markets and the success of new cancer treatments.

AstraZeneca said Friday that net income rose to $593 million from $340 million in the same period last year. Product sales increased 5.5% to $16.39 billion, driven by new drugs such as the bladder cancer treatment Imfinzi and lung cancer therapy Tagrisso.

Emerging market sales increased 14%, boosted by strong growth in China.

Nicholas Hyett, equity analyst at Hargreaves Lansdown in London, says the results vindicate CEO Pascal Soriot's strategy and show that "revenue growth is no longer a matter of faith" for investors.

Soriot promised investors that AstraZeneca's pipeline of new drugs would pay off when he fended off a takeover bid from Pfizer in 2014.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast